Literature DB >> 9216721

Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions.

B Marshall1, G Isidro, A G Martins, M G Boavida.   

Abstract

The genes responsible for the development of neuroblastoma following in vivo deletion or mutation are largely unknown. We have performed loss of heterozygosity studies on a series of 24 Portuguese primary neuroblastomas using 6 polymorphic markers located at chromosome 9p21 spanning the p16/MTS1/CDKN2, p15/MTS2/CDKN2B, and the interferon alpha and beta genes. Loss of heterozygosity was observed in 4 of the 24 tumors (17%), a somewhat lower percentage than a previous study that identified patients by a mass screening program. A correlation was also observed between 9p21 LOH and 1p36 LOH in our group of tumors. Two distinct regions of 9p21 deletion were observed: one located in the region adjacent to the markers D9S162 and D9S1747 and a second located centromerically of the p16 gene near the D9S171 marker. The latter region is exclusive of the p16 gene. This result suggests the presence of at least one other tumor suppressor gene at 9p21, apart from the p16 and p15 genes, which may be of importance to the development of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9216721     DOI: 10.1016/s0165-4608(96)00300-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

Review 1.  Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.

Authors:  J Mora; N K Cheung; B H Kushner; M P LaQuaglia; K Kramer; M Fazzari; G Heller; L Chen; W L Gerald
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

2.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

Review 3.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

4.  Rho GEFs in endothelial junctions: Effector selectivity and signaling integration determine junctional response.

Authors:  Siu P Ngok; Panos Z Anastasiadis
Journal:  Tissue Barriers       Date:  2013-11-15

Review 5.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

6.  Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

Authors:  John M Maris; George Hii; Craig A Gelfand; Shobha Varde; Peter S White; Eric Rappaport; Saul Surrey; Paolo Fortina
Journal:  Genome Res       Date:  2005-08       Impact factor: 9.043

7.  Bioinformatics analysis of recurrent deletion regions in neuroblastoma.

Authors:  Hasan Onur Caglar
Journal:  Med Oncol       Date:  2022-01-20       Impact factor: 3.064

8.  Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours.

Authors:  J Mora; M Alaminos; C de Torres; P Illei; J Qin; N-K V Cheung; W L Gerald
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.